Title |
Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers
|
---|---|
Published in |
BMC Medicine, February 2018
|
DOI | 10.1186/s12916-018-1026-6 |
Pubmed ID | |
Authors |
José M. Benito, María C. Ortiz, Agathe León, Luis A. Sarabia, José M. Ligos, María Montoya, Marcial Garcia, Ezequiel Ruiz-Mateos, Rosario Palacios, Alfonso Cabello, Clara Restrepo, Carmen Rodriguez, Jorge del Romero, Manuel Leal, María A. Muñoz-Fernández, José Alcamí, Felipe García, Miguel Górgolas, Norma Rallón, On behalf of ECRIS integrated in the Spanish AIDS Research Network |
Abstract |
Despite long-lasting HIV replication control, a significant proportion of elite controller (EC) patients may experience CD4 T-cell loss. Discovering perturbations in immunological parameters could help our understanding of the mechanisms that may be operating in those patients experiencing loss of immunological control. A case-control study was performed to evaluate if alterations in different T-cell homeostatic parameters can predict CD4 T-cell loss in ECs by comparing data from EC patients showing significant CD4 decline (cases) and EC patients showing stable CD4 counts (controls). The partial least-squares-class modeling (PLS-CM) statistical methodology was employed to discriminate between the two groups of patients, and as a predictive model. Herein, we show that among T-cell homeostatic alterations, lower levels of naïve and recent thymic emigrant subsets of CD8 cells and higher levels of effector and senescent subsets of CD8 cells as well as higher levels of exhaustion of CD4 cells, measured prior to CD4 T-cell loss, predict the loss of immunological control. These data indicate that the parameters of T-cell homeostasis may identify those EC patients with a higher proclivity to CD4 T-cell loss. Our results may open new avenues for understanding the mechanisms underlying immunological progression despite HIV replication control, and eventually, for finding a functional cure through immune-based clinical trials. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Mexico | 1 | 13% |
Spain | 1 | 13% |
United States | 1 | 13% |
United Kingdom | 1 | 13% |
Unknown | 4 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 75% |
Practitioners (doctors, other healthcare professionals) | 2 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 123 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Doctoral Student | 10 | 8% |
Student > Ph. D. Student | 8 | 7% |
Researcher | 7 | 6% |
Professor | 4 | 3% |
Student > Bachelor | 2 | 2% |
Other | 7 | 6% |
Unknown | 85 | 69% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 7% |
Agricultural and Biological Sciences | 9 | 7% |
Nursing and Health Professions | 5 | 4% |
Biochemistry, Genetics and Molecular Biology | 3 | 2% |
Psychology | 2 | 2% |
Other | 5 | 4% |
Unknown | 90 | 73% |